JP2019517813A5 - - Google Patents

Download PDF

Info

Publication number
JP2019517813A5
JP2019517813A5 JP2018566226A JP2018566226A JP2019517813A5 JP 2019517813 A5 JP2019517813 A5 JP 2019517813A5 JP 2018566226 A JP2018566226 A JP 2018566226A JP 2018566226 A JP2018566226 A JP 2018566226A JP 2019517813 A5 JP2019517813 A5 JP 2019517813A5
Authority
JP
Japan
Prior art keywords
antibody
seq
human
chain comprises
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018566226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517813A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/037533 external-priority patent/WO2017218691A1/en
Publication of JP2019517813A publication Critical patent/JP2019517813A/ja
Publication of JP2019517813A5 publication Critical patent/JP2019517813A5/ja
Pending legal-status Critical Current

Links

JP2018566226A 2016-06-16 2017-06-14 Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体 Pending JP2019517813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351054P 2016-06-16 2016-06-16
US62/351,054 2016-06-16
PCT/US2017/037533 WO2017218691A1 (en) 2016-06-16 2017-06-14 Humanized and chimeric monoclonal antibodies to cd81

Publications (2)

Publication Number Publication Date
JP2019517813A JP2019517813A (ja) 2019-06-27
JP2019517813A5 true JP2019517813A5 (enExample) 2020-07-27

Family

ID=60664252

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566226A Pending JP2019517813A (ja) 2016-06-16 2017-06-14 Ｃｄ８１に対するヒト化及びキメラモノクローナル抗体

Country Status (9)

Country Link
US (1) US10815306B2 (enExample)
EP (1) EP3471762A4 (enExample)
JP (1) JP2019517813A (enExample)
CN (1) CN109414492A (enExample)
BR (1) BR112018076247A2 (enExample)
CA (1) CA3027942A1 (enExample)
MA (1) MA45404A (enExample)
RU (1) RU2019100102A (enExample)
WO (1) WO2017218691A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7697695B2 (ja) 2020-01-21 2025-06-24 タボテック バイオテクノロジー（チャンスー）カンパニー リミテッド ＩＬ－１β受容体シグナル伝達に干渉する剤
JP2025536268A (ja) 2022-10-12 2025-11-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｃｄ８１

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US7910100B2 (en) 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
CN109485727A (zh) * 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
JP5769316B2 (ja) * 2009-08-06 2015-08-26 イムナス・ファーマ株式会社 Ａβオリゴマーに特異的に結合する抗体およびその利用
US20140030771A1 (en) 2010-06-09 2014-01-30 Richard C. Yu Compositions and methods for increasing oil production and secretion
CA2820134A1 (en) * 2010-12-06 2012-06-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
US8440797B2 (en) * 2010-12-06 2013-05-14 Dainippon Sumitomo Pharma Co., Ltd. Human monoclonal antibody
US9725517B2 (en) * 2012-10-26 2017-08-08 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Humanized monoclonal antibodies against the extracellular domain of human death receptor 5

Similar Documents

Publication Publication Date Title
JP6971153B2 (ja) 多重特異的ｎｋエンゲイジャータンパク質
CN107532188B (zh) Cd20结合分子及其用途
AU2014238546C1 (en) Humanized anti-CD134 (OX40) antibodies and uses thereof
CA3175140A1 (en) Novel anti-lilrb4 antibodies and derivative products
CN109475603A (zh) 抗pd-l1抗体
CA3044684A1 (en) Anti-sirp-alpha antibodies and methods of use thereof
IL268593B2 (en) Polypeptides and antibodies having increased cdc and/or agonistic activity and their uses in medicine
JP2018510636A5 (enExample)
JP2014519322A5 (enExample)
JP2015533853A5 (enExample)
WO2020227457A1 (en) Materials and methods for modulating t cell mediated immunity
JP2017537082A5 (enExample)
KR20240067052A (ko) 항-ccr8 항체
JP2019535306A5 (enExample)
KR20230093010A (ko) 신규 항-lilrb2 항체 및 유도체 생성물
AU2018241916A1 (en) PD-L1 and TA-MUC1 antibodies
JP2023518189A (ja) デルタ鎖媒介性免疫を調節するための材料及び方法
JP6548052B2 (ja) 抗体
KR20230156727A (ko) 항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
JP2019517813A5 (enExample)
AU2017320457A1 (en) CD20 antibodies
KR20240055016A (ko) 면역억제성 b 세포와 연관된 암을 치료하는 방법
RU2019100102A (ru) Гуманизированные и химерные моноклональные антитела против cd81
US20230265202A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
WO2023143565A1 (en) Anti-btla antibodies and uses thereof in treating cancer